產(chǎn)品編號 | bs-4561R-Gold |
英文名稱1 | Rabbit Anti-Bivalirudin/Gold Conjugated antibody |
中文名稱 | 膠體金標(biāo)記的比伐盧定(水蛭素類似物)抗體 |
別 名 | Bivalirudin; 128270-60-0 |
規(guī)格價格 | 100ul/2980元 購買 大包裝/詢價 |
說 明 書 | 100ul(10nm 15nm 35nm) |
產(chǎn)品類型 | 小分子抗體 |
研究領(lǐng)域 | 心血管 免疫學(xué) |
抗體來源 | Rabbit |
克隆類型 | Polyclonal |
交叉反應(yīng) | |
產(chǎn)品應(yīng)用 | IEM=1:20-200 ICA=1:20-200 ChIP=1:20-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
分 子 量 | 2.108kDa |
性 狀 | Lyophilized or Liquid |
濃 度 | 0.4mg/ml |
免 疫 原 | KLH conjugated synthetic peptide Bivalirudin (d-FPRPGGGGNGDFEEIPEEYL) |
亞 型 | IgG |
純化方法 | affinity purified by Protein A |
儲 存 液 | 0.02M TBS(pH8.2) with 1% BSA, 0.03% Proclin300. |
保存條件 | Store at 2-8 oC for 3-6 months. Avoid repeated freeze/thaw cycles. |
產(chǎn)品介紹 |
background: Bivalirudin is a specific and reversible direct thrombin inhibitor (DTI). Chemically, it is a synthetic congener of the naturally occurring drug hirudin (found in the saliva of the medicinal leech Hirudo medicinalis). Bivalirudin is a DTI that overcomes many limitations seen with indirect thrombin inhibitors, such as heparin. Bivalirudin is a short, synthetic peptide that is potent, highly specific, and a reversible inhibitor of thrombin. It inhibits both circulating and clot-bound thrombin, while also inhibiting thrombin-mediated platelet activation and aggregation. Bivalirudin has a quick onset of action and a short half-life. It does not bind to plasma proteins (other than thrombin) or to red blood cells. Therefore, it has a predictable antithrombotic response. There is no risk for Heparin Induced Thrombocytopenia/Heparin Induced Thrombosis-Thrombocytopenia Syndrome (HIT/HITTS). It does not require a binding cofactor such as antithrombin and does not activate platelets. These characteristics make bivalirudin an ideal alternative to heparin. Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |